American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Background: Venous thromboembolism (VTE) is a common complication among patients
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and …
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
TL Ortel, I Neumann, W Ageno, R Beyth… - Blood …, 2020 - ashpublications.org
In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …
Review included limited searches for new evidence and discussion of the search results …
Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report
Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …
Editor's Choice–European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis
SK Kakkos, M Gohel, N Baekgaard… - European Journal of …, 2021 - ejves.com
2.1. 1. Epidemiology and burden of the disease. The annual incidence of first episode of
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …
symptomatic DVT in the adult population ranges from 50 to 100 per 100 000 population, with …
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report
Background We update recommendations on 12 topics that were in the 9th edition of these
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
guidelines, and address 3 new topics. Methods We generate strong (Grade 1) and weak …
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event …
Objectives To determine the rate of a first recurrent venous thromboembolism (VTE) event
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …
after discontinuation of anticoagulant treatment in patients with a first episode of unprovoked …
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and …
Venous thromboembolism (VTE) incidence increases sharply with age (Figure 1) and
appears steady over the last 25 years, despite preventive strategies. 1 Women are more …
appears steady over the last 25 years, despite preventive strategies. 1 Women are more …
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis
Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism
Hokusai-VTE Investigators - New England journal of medicine, 2013 - Mass Medical Soc
Background Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin
in patients with venous thromboembolism is unclear. Methods In a randomized, double …
in patients with venous thromboembolism is unclear. Methods In a randomized, double …
Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice …
Background This article addresses the treatment of VTE disease. Methods We generated
strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A) …
strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A) …